Venus Remedies share news, announcements and annual reports
NSE: VENUSREMBSE: 526953Pharmaceuticals & BiotechnologySmall Cap
Venus Remedies Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1995 on BSE, Dec 2006 on NSE
Last close ₹1,238.60down ₹50.70 (3.93%)BSE ₹1,231.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,289.30.
30 Oct: open ₹1,290.00, high ₹1,319.00, low ₹1,225.10
52-week range of traded prices to 30 Oct 2026
₹432.10Low, 31 Oct 2025₹2,044.30High, 29 Jun 2026
- Under NSE's long-term additional surveillance, stage IV, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,656 Cr1,337th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 13.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.81%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 48,127
Venus Remedies share news and announcements
697 announcements, routine notices left out, newest first. Page 5 of 14.
Aug 2022
23 Aug · Meeting
Jul 2022
29 Jul · Meeting
25 Jul · Meeting
11 Jul · General updates
Jun 2022
4 Jun · Related Party Transaction
May 2022
28 May · Communication to shareholders as per Reg 30
27 May · Communication to shareholders as per Reg 30
27 May · Results
27 May · Communication to shareholders as per Reg 30
Apr 2022
13 Apr · General updates
Mar 2022
Feb 2022
Jan 2022
31 Jan · Results
31 Jan · Board meeting
20 Jan · Board meeting
Dec 2021
30 Dec · Legal
Exchange has sought clarification from Venus Remedies Limited with respect to announcement dated 30-Dec-2021, regarding appointment of Dr. Savita Gupta as Additional Director (Non- Executive Independent Director) of the company.On basis of above the Company is required to clarify following -1. Confirmation in compliance with SEBI Letter dated June 14, 2018 read alongwith NSE Circular dated June 20, 2018.The response of the Company is awaited.30 Dec · Management
23 Dec · Board meeting
Oct 2021
30 Oct · Results
30 Oct · Board meeting
18 Oct · Board meeting
13 Oct · Updates
Sep 2021
20 Sep · Meeting
Aug 2021
12 Aug · Results
12 Aug · Board meeting
Jul 2021
19 Jul · Updates
Jun 2021
8 Jun · Related Party Transactions
May 2021
31 May · Results
31 May · Board meeting
Apr 2021
13 Apr · Legal
Exchange has sought clarification from Venus Remedies Limited with respect to announcement dated 13-Apr-2021, regarding Press release dated April 13, 2021, titled "Venus Remedies Enters into Partnership with West Pharmaceutical Services, Inc. to Launch Cloti-Xa (Enoxaparin Prefilled Syringes) in India with NovaGuard SA Pro Safety System.On basis of above the Company is required to clarify following: 1. Date of launch;2. Whether caters to domestic/ international market;3. Name of the countries in which the product is launched (in case of international).The response of the Company is awaited.